This Study performs unique rapid on-site measurement using patient whole blood and positions Company to move forward with multiple initiatives ACTON, Mass., Jan. 13, 2022 (GLOBE NEWSWIRE) -- Bluejay ...
ACTON, Mass., May 19, 2023 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a medical technology company developing rapid diagnostics on its Symphony platform ...
This Study performs unique rapid on-site measurements of interleukin-6 (IL-6) and positions Company to move forward with multiple initiatives. “Sepsis is a leading cause of hospitalization and ...
ACTON, Mass., July 06, 2022 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay”, “the Company”), a medical diagnostics company focused on developing cost-effective, rapid, ...
ACTON, Mass., Dec. 29, 2025 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”) announced that it has completed commercial-scale production of both polyclonal and ...
An update from Bluejay Diagnostics ( (BJDX)) is now available. On December 29, 2025, Bluejay Diagnostics announced it had completed commercial-scale production of both polyclonal and monoclonal ...
The Australian company will retain rights for an end-stage kidney disease indication currently being tested in a Phase 3 trial while Lilly explores other uses.
This Study performs unique rapid on-site measurements of interleukin-6 (IL-6) and positions Company to move forward with multiple initiatives. ACTON, Mass., Dec. 27, 2023 (GLOBE NEWSWIRE) -- Bluejay ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results